Media coverage about Mednax (NYSE:MD) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mednax earned a news impact score of 0.09 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.5720677880569 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the media stories that may have impacted Accern’s rankings:

Several analysts have commented on the stock. Jefferies Group reiterated a “hold” rating and set a $44.00 target price on shares of Mednax in a research report on Friday, November 3rd. KeyCorp upgraded shares of Mednax from a “sector weight” rating to an “overweight” rating and set a $51.00 target price for the company in a research report on Sunday, September 17th. Citigroup dropped their target price on shares of Mednax from $52.00 to $47.00 and set a “neutral” rating for the company in a research report on Friday, November 3rd. Piper Jaffray Companies assumed coverage on shares of Mednax in a research report on Wednesday. They set an “overweight” rating and a $58.00 target price for the company. Finally, BMO Capital Markets assumed coverage on shares of Mednax in a research report on Monday, October 16th. They set a “market perform” rating and a $46.00 target price for the company. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $53.70.

Mednax (MD) traded up $0.03 during trading on Friday, hitting $51.10. 2,122,600 shares of the stock were exchanged, compared to its average volume of 1,098,945. Mednax has a one year low of $40.56 and a one year high of $72.13. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.37 and a current ratio of 1.37. The firm has a market cap of $4,790.00, a P/E ratio of 15.77, a price-to-earnings-growth ratio of 1.66 and a beta of 0.40.

Mednax (NYSE:MD) last posted its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.87. Mednax had a net margin of 7.76% and a return on equity of 10.80%. The company had revenue of $868.95 million during the quarter, compared to the consensus estimate of $864.78 million. During the same period in the prior year, the business posted $1.09 EPS. The company’s quarterly revenue was up 4.9% on a year-over-year basis. analysts expect that Mednax will post 3.1 earnings per share for the current year.

In other Mednax news, Director Cesar L. Alvarez sold 10,668 shares of the stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $42.59, for a total value of $454,350.12. Following the transaction, the director now directly owns 44,215 shares of the company’s stock, valued at approximately $1,883,116.85. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total transaction of $154,740.00. Following the transaction, the insider now directly owns 35,569 shares in the company, valued at $1,834,649.02. The disclosure for this sale can be found here. Corporate insiders own 2.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Insider Buying and Selling by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax and related companies with Analyst Ratings Network's FREE daily email newsletter.